Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

2.34 1.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.25

Max

2.33

Põhinäitajad
By Trading Economics
Sissetulek	14M -1M
Müük	16M 21M
Aktsiakasum	-0.003
Kasumimarginaal	-4.943
Töötajad	81
EBITDA	15M 657K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+95.28% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	276M 986M
Eelmine avamishind	0.6
Eelmine sulgemishind	2.34

Uudiste sentiment

By Acuity

50%

156 / 340 Pingereas Healthcare

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

95.28% tõus

12 kuu keskmine prognoos

Keskmine 4.55 USD 95.28%

Kõrge 6 USD

Madal 3.1 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

156 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.